Categories: News

ESHRE 41st Annual Meeting: Older paternal age linked to higher miscarriage risk and lower live birth rates in donor egg IVF cycles

A new international study presented today at the 41st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) reveals that IVF cycles involving male partners over the age of 45 carry significantly increased miscarriage risks and lower live birth rates – even when young donor eggs are used.

- Advertisement -

PARIS, June 29, 2025 /PRNewswire/ — By isolating paternal age from female reproductive factors through the exclusive use of donor eggs from young women, the study provides robust evidence that male age plays a critical role in reproductive success, challenging the common assumption that sperm age has little impact once fertilisation occurs.

- Advertisement -

The retrospective study analysed 1,712 first oocyte donation cycles conducted between 2019 and 2023 across six IVF centres in Italy and Spain. All cycles used fresh donor oocytes and frozen sperm from male partners, with only the first single blastocyst transfer included. Female recipients had a mean age of 43.3 years.

- Advertisement -

Participants were divided into two groups: men aged 45 or younger (n=1,066) and those over 45 (n=646). While fertilisation rates and embryo development were comparable between groups, significant differences emerged in clinical outcomes.

- Advertisement -

Miscarriage rates were notably higher among couples where the male partner was over 45, reaching 23.8% compared to 16.3% in the younger paternal age group. Similarly, live birth rates were significantly lower in the older paternal age group, at 35.1% versus 41% for men aged 45 or younger.

- Advertisement -

Discussing the findings, Dr. Maria Cristina Guglielmo, Embryologist at Eugin Italy, said, “Traditionally, maternal age has been the central focus in reproductive medicine, but our results show that the age of the male partner also plays a crucial and independent role. Even when using eggs from young, healthy donors and transferring only a single, high-quality embryo, we observed poorer outcomes in men over 45.”

- Advertisement -

She also emphasised the importance of examining how paternal age affects the health of offspring. “There is growing evidence linking advanced paternal age to an increased risk of neurodevelopment disorders in children. Our future work will investigate the long-term health and developmental outcomes of children conceived through donor egg cycles with older fathers, where maternal factors are minimised, to isolate paternal effects more clearly.”

- Advertisement -

The study abstract will be published today in Human Reproduction, one of the world’s leading reproductive medicine journals.

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/eshre-41st-annual-meeting-older-paternal-age-linked-to-higher-miscarriage-risk-and-lower-live-birth-rates-in-donor-egg-ivf-cycles-302489595.html

- Advertisement -

Recent Posts

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026…

2 hours ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI,…

2 hours ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing…

2 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

2 hours ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

2 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

2 hours ago